Insulin Therapy and GLP-1 analogues Dr. Spurgeon Dept of Endocrinology, Christian Medical College, Vellore.

Slides:



Advertisements
Similar presentations
Advanced Pumping. Objectives: Identify situations to utilize temporary basal rate in pump therapy patients. Identify examples of when to use combination.
Advertisements

Oral Hypoglycemic Drugs And Classifications
 GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose  Type 2 diabetics little incretin effect  Reduced GLP-1 secretion.
The New HbA1c HbA1c – DCCT (%) HbA1c – IFFC (mmol/mol)
Diabetes (abridged!). Who needs screening for DM? Age >45 Obese – BMI >25 1 st degree relative with DM Racial groups: –African American –Hispanic American.
Insulin Diabetes Outreach (June 2011). 2 Insulin Learning outcomes >Understand the difference between insulin therapy in type 1 diabetes as compared to.
Islets of Langerhan. Prof. K. Sivapalan Islets of Langerhan2 Histology. A cells 20 % [glucogon] B cells 50% [Insulin] D cells 8% [somatostatin]
Diabetes Mellitus.
DIABETES MEDICATION UPDATE A. Sami Wood, MS, RD/LD,CDE Center For Diabetes Education OSUMC.
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Introduction to Clinical Pharmacology Chapter 42- Antidiabetic Drugs.
INSULIN STRATEGIES IN TYPE 2 DIABETES. The epidemic of type 2 diabetes and the recognition that achieving specific glycemic goals can substantially reduce.
Dr. A. R. GOHARIAN Endocrinologist
Chapter 36 Agents Used to Treat Hyperglycemia and Hypoglycemia.
Insulin therapy.
LONG TERM BENEFITS OF ORAL AGENTS
Drugs used in Diabetes Dr Sally Hudson. BIGUANIDES reduce output of glucose from the liver and enhances uptake and use of glucose by muscle cells ExampleADVANTAGESDISADVANTAGESCOSTCaution.
Kathryn A. Hanavan ANP-BC; BC-ADM Harold Schnitzer Diabetes Health Center September 12,
CARE OF PATIENTS WITH DIABETES MELLITUS JANNA WICKHAM RN MSN LSSC FALL 2013 Chapter 20.
INSULIN THERAPY IN TYPE 1 DIABETES
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
oral hypoglycemic agents
Oral Hypoglycemic Drugs
Clinical Update in Type 2 Diabetes A Case Discussion Dr. Yancey R. Holmes, MD, FACE Ohio Valley Endocrinology.
Guidelines for Diabetes Management September 20, 2012 Margaret Pochay RD CDE.
Basal and Meal Time Insulin Case Study
Journal Club 2009 年 1 月 29 日(木) 8 : 20 ~ 8 : 50 B 棟 8 階カンファレンスルーム 薬剤部 TTSP 石井 英俊.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Use of Insulin in treatment of diabetes mellitus Prof. Hanan Hagar.
Pharmacology of Diabetes Mellitus 2 Dr Emma Baker Consultant Physician/Senior Lecturer in Clinical Pharmacology.
Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Insulin Use in Diabetes Mellitus Jennifer Beggs. Introduction History of insulin Manufacture and secretion The insulin receptor Homeostatic role Insulin.
Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 4 of 5.
Insulin Initiation In Primary Care Dr Arla Ogilvie Endocrinologist Watford General Hospital West Herts Hospitals NHS Trust.
Endocrine Physiology The Endocrine Pancreas Dr. Khalid Al-Regaiey.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
DH206: Pharmacology Chapter 21: Diabetes Mellitus Lisa Mayo, RDH, BSDH.
Technology to Assist with Diabetes Care February 4, 2011 Margaret Pochay RD CDE.
Diabetes Mellitus: Prevention & Treatment Medical surgical in nursing /02/01.
#4 Management of Diabetes Mellitus. 5 Components of Diabetes Management 5 Components of Diabetes Management Farrell, M. (2005). Textbook of Medical-Surgical.
Endocrine System KNH 411. Diabetes Mellitus 7% of population; 1/3 undiagnosed $132 billion in health care Sixth leading cause of death Complications of.
Should we be using the new insulins in T2DM? Ian Gallen MD FRCP Community Diabetologist Royal Berkshire Hospital.
ADDITIONAL SLIDES FOR ASSIST WITH COMPREHENSION OF LAB CONTENT-MODULE FIVE-DM DENISE TURNER, MS-N.ED, RN, CCRN.
Journal Club 9/15/11 Sanaz Sakiani, MD 1 st Year Endocrine Fellow Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics.
Diabetes mellitus.
Focus on Diabetes Mellitus NUR 171. How insulin works dia2.us.elsevierhealth.com/ondemand/archieAnimations/423.flv.
Dr. Mansour Alzahrani. متى اكتشف داء السكري؟ داء السكري في الحضارة الهندية والصينية القديمة اسهامات علماء المسلمين في داء السكري.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.
Diabetes & selected medications Medical-surgical Nursing Chapter 64-Iggy-Pg 1300 NUR 152 Mesa Community College.
Small concise points on Insulin
Insulin Initiation and Titration
Jill Little Diabetes Specialist Nurse
GLP-1 Agonist:When to start ?
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS
Interventions for Clients with Diabetes Mellitus
Endocrine System KNH 411.
Endocrine System KNH 411.
Jill Little Diabetes Specialist Nurse
Insulin Safety know your insulins! There are many! Humalog® Mix25 Humalog® Mix50 Humulin® I Humulin® M3 Humulin® S Humalog® U-100 Humalog® U-200.
oral hypoglycemic agents
Diabetes.
Endocrine System KNH 411.
Introduction to Clinical Pharmacology Chapter 42- Antidiabetic Drugs
Approach to starting and adjusting insulin in type 2 diabetes.
Endocrine System KNH 411.
Endocrine System KNH 411.
Endocrine System KNH 411.
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
Insulin Delivery Systems Atlanta Diabetes Associates
Insulin in Type 2 Diabetes
Presentation transcript:

Insulin Therapy and GLP-1 analogues Dr. Spurgeon Dept of Endocrinology, Christian Medical College, Vellore

 -cell function (%) Year s Progressive Beta Cell failure in Type II Diabetes Mellitus

 Stimulates entry of amino acids into cells, enhancing protein synthesis  Enhances fat storage (lipogenesis) and prevents mobilization of fat for energy (Lipolysis and Ketogenesis)  Stimulates entry of glucose into cells for utilization as energy source  Promotes storage of glucose as glycogen in muscle and liver cells (glycogenesis) What are the anabolic effects of Insulin?

“The Magnificent Seven” When should Insulin be used in When should Insulin be used in Type 2 diabetes mellitus? Type 2 diabetes mellitus?

1. Type 2 diabetes not controlled with maximal doses of Oral Hypoglycaemic agents What do you mean by maximal doses of OHAs? Metformin 2500/3000mg a day + Glipizide 20mg/glibenclemide15-20mg/day Gliciazide 320mg/ Glimepride 6-8mg/day + Rosiglitazone 8mg/ Pioglitazone 45mg/day When should Insulin be used in When should Insulin be used in Type 2 diabetes mellitus? Type 2 diabetes mellitus?

2. Type 2 diabetes during periods of physiological stress (surgery, infection) Continue OHAs simultaneously. Stop metformin in case of severe infections or impending reduction in renal perfusion When should Insulin be used in When should Insulin be used in Type 2 diabetes mellitus? Type 2 diabetes mellitus?

3. Pregestational diabetes Metformin may be continued Discontinue other medications When should Insulin be used in When should Insulin be used in Type 2 diabetes mellitus? Type 2 diabetes mellitus?

4. Use of parenteral nutrition or high-caloric supplements Indications of Insulin therapy?

5. Diabetic ketoacidosis (DKA)/Hyperosmolar hyperglycemic nonketotic syndrome (HHNS) Indications of Insulin therapy?

6. Progressive complications: proliferative retinopathy/maculopathy, progressive or painful neuropathy For rapid control and tighter adjustment Indications of Insulin therapy?

7. Chronic Renal Failure For all above a creatinine of 4.0mg/dl Cutoffs for other OHAs:- Metformin: 1.5mg/dl Glimeperide/Glibenclemide: 2.0mg/dl Glipizide: 2.5mg/dl Pioglitazone/Rosiglitazone: 4.0mg/dl Indications of Insulin therapy?

What is the normal insulin secretory pattern? Basal Bolus

How does one classify the types of insulin?  Generally classified according to peak effect and duration of action  Short acting: regular/ Lispro /Aspart  Intermediate acting: NPH/ Lente  Premixed:(30/70), (50/50)

What are the types of Insulin ? Short acting Intermediate acting Long acting Analogs : Regular insulin : Lente insulin NPH insulin : Ultralente Short acting : Lispro, Aspart Long acting : Glargine

What is the time action profile of different types of insulins?

What are the types of insulin regimens? Premixed regimen Split mix regimen Basal bolus regime (multidose) Bedtime dosing alone (NPH/Lente/Glargine) Infusion

Premixed insulin:action

Premixed insulin Premixed(30/70): Regular: 30 % NPH : 70% Premixed (50/50): Regular 50% NPH 50% Premixed Analogs Biphasic insulin aspart (30/70) 30% : Aspart 70% : protaminated aspart

Insulin Therapy Regimens  Usual starting dose: unit/kg/day

Premixed insulin Dose adjustment: The fasting sugar depends on the night dose of insulin The post breakfast sugar depends on the morning dose of insulin Rough calculation increase the insulin by one unit to reduce the sugars by 25mg/dl

Self Monitoring is crucial Self Monitoring is crucial Glucometers At least 6-8 times a week ideally

Premixed insulin Advantages more accurate dosing lesser injections Pen devices administer premixed forms Disadvantages Fine tuning may not be possible Strict meal pattern Nocturnal hypoglycemia May need “diet changes for insulin” rather than “insulin changes for diet”

Split-mixed insulin Common combinations: Short acting plus intermediate acting in a syringe:- Regular + NPH

How to adjust insulin doses in a split mix NPH Regular Increase regular insulin Regular meal

How to adjust insulin doses in a split mix Regular NPH Reduce regular insulin Regular meal

How to adjust insulin doses in a split mix ? Regular NPH Increase NPH insulin Peak action of NPH meal

How to adjust insulin doses in a split mix ? Regular NPH Regular Reduce NPH insulin Peak action of NPH Meal

Split-mixed insulin Advantages Less hypoglycaemia, with fine tuning More physiologic Adjustable meal pattern Disadvantages More patient education required Cumbersome mixing Pen device not feasible if two injections are planned for.

Bedtime NPH/Glargine Continue daytime oral hypoglycaemic agents: especially sulphonylureas (The BIDS regimen) Advantage: Once daily dosing Easy dose titration Disadvantage: May need premeal bolus

NPH NPH

Glargine Glargine

Bedtime Long- acting Advantages Single Daily dosing Disadvantages Suitable for only <15% of Type 2 Diabetes

Basal bolus regime(multidose) Rarely used in Type 2 Rarely used in type 2 diabetes

Starting insulin in type 2 diabetes - patient on full dose OHA Continue the OHA Start on insulin (approx 0.2 U/kg/day,morning 2/3, evening 1/3) Reassess control with SMBG & titrate dosage Consider adding short acting premeal bolus if uncontrolled PPBG Consider withdrawing sulphonylurea

Can Oral hypoglycaemic agents be continued at the same time with insulin? Metformin Best continued if renal function is normal. May reduce insulin requirements by 15-30%. Adjunctive weight reducing effect Thiazolidinediones May be continued with insulin. Can reduce insulin requirements from 15-60% Major issue of weight gain, accentuated by insulin: 7.5%. 15%>5kg.

Can Oral hypoglycaemic agents be continued at the same time with insulin? Sulphonylureas Glimeperide: doses of 2-4mg a day have a peripheral GLUT-4 activity reducing insulin requirement by 10-20%. Glipizide and Glibenclemide can reduce insulin requirements by 5-15%. Unpredictable- recommended previously in those with high C-peptide levels

Used in situations like DKA, immediate control of sugars monitor sugars more frequently monitor potassium over lap with long acting insulin Used in situations like DKA, immediate control of sugars monitor sugars more frequently monitor potassium over lap with long acting insulin Infusion

GLP-1 Analogues accounted for by following effects: – stimulation of insulin secretion – inhibition of glucagon release – delay of gastric emptying – increase of insulin sensitivity

Stimulates insulin gene expression Stimulates insulin biosynthesis Stimulates -cell proliferation and survival Stimulates differentiation of exocrine cells or islet precusors toward -cell phenotype

When do you start? As mono or combination therapy Obese type 2 Diabetics Along with oral drugs.

Development of Exenatide: An Incretin Mimetic Exenatide (Exendin-4) – Synthetic version of salivary protein found in the Gila monster – Approximately 50% identity with human GLP-1 Binds to known human GLP-1 receptors on cells in vitro Resistant to DPP-IV inactivation

DOSAGE AND ADMINISTRATION Inject subcutaneously within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart. Initiate at 5 mcg per dose twice daily; increase to 10 mcg twice daily after 1 month based on clinical response. Initiation with 5 mcg reduces the incidence and severity of gastrointestinal side effects.

BYETTA is supplied as 250 mcg/mL exenatide in: 5 mcg per dose, 60 doses, 1.2 mL prefilled pen 10 mcg per dose, 60 doses, 2.4 mL prefilled pen

Contraindicated-- Type 1 DM History of pancreatic disease Should not be used in patients with severe renal impairment (creatinine clearance < 30 mL/min). Severe GI problems Hypersenitivity to drug

Insulin administration is suitably as premixed fashion for most type 2 diabetes. Split-mix may be required in a subset. The neccessity of self blood glucose monitoring as a accessory is emphasized. Summarizing……..